BiotechTube
Neurix

Neurix

Basel, Switzerland· Est.
neurix.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Neurix is a private, Switzerland-based biotech company leveraging human iPSC technology to create advanced 3D in vitro models of the brain for preclinical research. Its core business is providing specialized research services and proprietary model systems, such as its BlastomaBrain™ glioblastoma model, to pharmaceutical and academic partners to improve the predictability of neuroscience drug discovery. The company is led by a team with strong scientific and business backgrounds and has been supported by European research funding. Neurix operates as a pre-revenue platform and services company, focusing on neurodegenerative diseases and neuro-oncology.

Neurodegenerative DiseasesNeuro-oncology

Technology Platform

Development of physiologically relevant 3D in vitro cellular model systems derived from human induced pluripotent stem cells (iPSCs) to replicate brain physiology and pathology for drug discovery and research.

Opportunities

The high failure rate of neurological drug candidates creates a strong demand for more predictive human-relevant preclinical models.
Growing regulatory and ethical shifts away from animal testing further accelerate the need for advanced in vitro platforms like those developed by Neurix.

Risk Factors

The company is pre-revenue and reliant on grant funding and partnerships, creating financial sustainability risk.
The technology faces competition and must continually prove its predictive value and reproducibility to gain widespread adoption in a conservative pharmaceutical industry.

Competitive Landscape

Neurix competes in the growing market for iPSC-derived research models, facing competition from large life science tools companies (e.g., STEMCELL Technologies, Takara Bio), contract research organizations (CROs) offering specialized services, and other academic spin-offs. Differentiation is based on disease-specific model sophistication, particularly in complex areas like glioblastoma invasion.

More companies in Switzerland →